Project description
New software to analyse anti-cancer drugs
Cancer treatment today is based on mutation analysis of cancer DNA using next-generation sequencing data. Advanced cancer drugs are expensive and their associated costs are posing big challenges for healthcare budgets. The EU-funded RASMAC project is developing a new software for analyses of tumours from DNA sequencing data. The aim is to optimise the use of targeted anti-cancer therapies. The project is being coordinated by the Swedish company Oncodia, which specialises in the development of technologically advanced software for sequencing analysis of cancers. The project will complete a business plan and a market feasibility study for the commercialisation of their product.
Objective
"As the incidence and prevalence of cancer increases worldwide, advanced anti-cancer drugs have become one of the key cost centres in healthcare budgets. This is a major societal challenge for the EU and global decision makers. Nowadays, modern anti-cancer therapies are expensive and are based on mutation analysis of cancer DNA Next-Generation-Sequencing data. However, state-of-the-art software used to analyse this data lack diagnostic accuracy and regulatory approvals.
Oncodia aims to address this market gap by developing RASMAC – software for analyses of tumours DNA sequencing data - to optimise the use of targeted anti-cancer therapies. The most innovative aspect of RASMAC lies in the deterministic algorithms that make it possible to accurately identify cancer mutations. We aim to set a new standard for diagnostic accuracy in mutation analysis in cancer that will lead to the right therapy for every patient.
Oncodia is well-positioned to disrupt the underserved market for cancer mutation analysis because of the expertise of multi-skilled team and the quality of previous projects (EU FP7 INNOVATION). Oncodia is the company able to uniquely deliver technologically superior, regulatory approved and cost-effective software. The innovativeness of our product has been recently confirmed through ""Attractive Innovation Project Award"" from Uppsala University Innovation.
During the Phase 1 Project, Oncodia will develop a business plan for the development and commercialisation of RASMAC. Specific objectives of this project are to design a study to improve the performance of the product and to conduct a market feasibility assessment to optimize go-to-market plan. The Phase 1 project is an important step on Oncodia’s journey to facilitate access to better DNA-based diagnostic routines for cancer patients worldwide. If successful, the project will take Oncodia to a new level of competitiveness and growth.
"
Fields of science
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
753 23 UPPSALA
Sweden
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.